Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ466MR)

This product GTTS-WQ466MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ466MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11590MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ5576MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ1295MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ13684MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ10481MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ8977MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ14952MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ4415MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW